Therapeutic Decisions In Multiple Sclerosis: Moving Beyond Efficacy

IMPORTANCE: Several innovative disease-modifying treatments (DMTs) for relapsing remitting multiple sclerosis (RRMS) have been licensed recently, or are in late-stage development. The molecular targets of several of these DMTs are well defined. All affect at least one of four properties: (1) immune...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Brück, Wolfgang, Ralf, Gold, Lund, Brett T., Celia, Oreja-Guevara, Prat, Alexandre, Spencer, Collin M., Steinman, Lawrence, Mar, Tintoré, Vollmer, Timothy, Weber, Martin S., Weiner, Leslie P., Ziemssen, Tjalf, Zamvil, Scott S.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106803/
https://ncbi.nlm.nih.gov/pubmed/23921521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2013.3510
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares